| abstract |
The present invention addresses the problem of providing a novel suicide gene system which allows for control of a chimeric-antigen-receptor gene-modified lymphocyte after being administered using a highly safe method, in order to further advance clinical applications of CAR therapies. According to the present invention, a genetically modified lymphocyte which expresses a chimeric antigen receptor is prepared by introducing, into a target cell, a target antigen-specific chimeric antigen receptor gene, and a first nucleic acid construct which intracellularly produces an siRNA which targets the NUDT15 gene and/or a second nucleic acid construct which intracellularly produces an siRNA which targets the TPMT gene. |